Treatment of Unresectable BRAF V600E , TERT -Mutated Differentiated Papillary Thyroid Cancer With Dabrafenib and Trametinib.

Autor: Bapat N; Department of Endocrinology, The George Washington University School of Medicine & Health Sciences, Washington, DC 20037, USA., Ferraro T; Division of Otolaryngology-Head and Neck Surgery, The George Washington University School of Medicine & Health Sciences, Washington, DC 20037, USA., Esper L; Department of Endocrinology, The George Washington University School of Medicine & Health Sciences, Washington, DC 20037, USA., Joshi AS; Division of Otolaryngology-Head and Neck Surgery, The George Washington University School of Medicine & Health Sciences, Washington, DC 20037, USA., Haroun F; Division of Hematology and Oncology, The George Washington University School of Medicine & Health Sciences, Washington, DC 20037, USA., Baldwin CK; Department of Endocrinology, The George Washington University School of Medicine & Health Sciences, Washington, DC 20037, USA.
Jazyk: angličtina
Zdroj: JCEM case reports [JCEM Case Rep] 2024 Jul 30; Vol. 2 (8), pp. luae112. Date of Electronic Publication: 2024 Jul 30 (Print Publication: 2024).
DOI: 10.1210/jcemcr/luae112
Abstrakt: Complete surgical resection of differentiated papillary thyroid cancer (PTC) is associated with an excellent prognosis. However, for locally invasive PTC, disease-specific morbidity and mortality increases when microscopic margin negative resection (R0) or complete macroscopic resection (R1) is not feasible. Neoadjuvant dabrafenib and trametinib (DT) used in BRAF V600E -positive, unresectable anaplastic thyroid cancer has allowed for R0 or R1 resection and improved survival rates. We demonstrate feasibility of using neoadjuvant DT in a patient with BRAF V600E and TERT -mutated PTC for whom R0/R1 resection was initially aborted due to predicted unacceptable morbidity. The patient was treated with neoadjuvant DT for 5 months, at which time disease was undetectable on imaging with near resolution on final pathology; however, subsequent rapid recurrence after discontinuation of neoadjuvant DT occurred. Neoadjuvant DT offers promise in future cohorts of patients with locally invasive BRAF V600E and TERT -mutated PTC for whom neoadjuvant therapy can reduce surgical morbidity while still allowing for R0/R1 resection.
(Published by Oxford University Press on behalf of the Endocrine Society 2024.)
Databáze: MEDLINE
Externí odkaz: